Pharmaceutical giant Eli Lilly announced that their eczema medication Ebglyss demonstrated sustained effectiveness over four years in treating severe skin conditions. The monthly injection provided significant itch relief and skin clearance for patients with moderate-to-severe atopic dermatitis.
Pharmaceutical company Eli Lilly announced Friday that their eczema medication demonstrated sustained effectiveness in a comprehensive post-marketing research study, providing patients with relief from chronic itching for as long as four years.
The medication, known as Ebglyss, received U.S. approval in 2024 and requires monthly injections to treat moderate-to-severe atopic dermatitis, a condition characterized by severe itching and skin inflammation.
The treatment is designated for adults and children aged 12 and above who suffer from moderate-to-severe eczema and cannot effectively use topical medications applied to the skin.
According to Lilly’s findings, most participants in the research achieved nearly complete skin healing and significant itch reduction after receiving continuous treatment for up to four years.
The company reported that Ebglyss maintained its established safety record during the study’s initial year, with no unexpected adverse effects discovered regardless of how frequently patients received doses.
Researchers plan to extend the study for one additional year of treatment observation.
Previously, Lilly published findings from a separate clinical trial demonstrating that Ebglyss maintained effective results when administered every four to eight weeks. The pharmaceutical company has forwarded this information to the U.S. Food and Drug Administration seeking potential modifications to the drug’s labeling requirements.
Tehran Expected to Respond to Washington Peace Proposal Today
Former Chelsea Star Catarina Macario Joins San Diego Wave Through 2030
Slovenian PM Seeks Coalition Partners After Razor-Thin Election Victory
Federal Investigators Issue Subpoenas in Major Hollywood Studio Merger Review